1. Home
  2. FEIM vs ANL Comparison

FEIM vs ANL Comparison

Compare FEIM & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frequency Electronics Inc.

FEIM

Frequency Electronics Inc.

HOLD

Current Price

$48.95

Market Cap

439.6M

Sector

Industrials

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$8.57

Market Cap

406.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEIM
ANL
Founded
1961
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Electrical Products
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
439.6M
406.5M
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
FEIM
ANL
Price
$48.95
$8.57
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$42.50
$16.00
AVG Volume (30 Days)
188.0K
185.4K
Earning Date
03-11-2026
04-20-2026
Dividend Yield
N/A
N/A
EPS Growth
316.95
N/A
EPS
0.41
N/A
Revenue
$69,811,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$21.73
N/A
P/E Ratio
$113.95
N/A
Revenue Growth
26.30
N/A
52 Week Low
$14.41
$0.88
52 Week High
$61.47
$12.09

Technical Indicators

Market Signals
Indicator
FEIM
ANL
Relative Strength Index (RSI) 53.65 59.18
Support Level $47.54 $1.36
Resistance Level $59.68 $9.98
Average True Range (ATR) 3.39 0.86
MACD 0.43 0.03
Stochastic Oscillator 88.79 81.20

Price Performance

Historical Comparison
FEIM
ANL

About FEIM Frequency Electronics Inc.

Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: